首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   649篇
  免费   34篇
耳鼻咽喉   4篇
儿科学   55篇
妇产科学   19篇
基础医学   166篇
口腔科学   6篇
临床医学   40篇
内科学   73篇
皮肤病学   18篇
神经病学   28篇
特种医学   85篇
外科学   93篇
综合类   13篇
预防医学   19篇
眼科学   2篇
药学   27篇
中国医学   2篇
肿瘤学   33篇
  2022年   6篇
  2021年   13篇
  2020年   12篇
  2019年   9篇
  2018年   10篇
  2017年   8篇
  2016年   7篇
  2015年   5篇
  2014年   18篇
  2013年   23篇
  2012年   23篇
  2011年   16篇
  2010年   21篇
  2009年   24篇
  2008年   20篇
  2007年   13篇
  2006年   19篇
  2005年   22篇
  2004年   18篇
  2003年   20篇
  2002年   19篇
  2001年   5篇
  2000年   14篇
  1999年   13篇
  1998年   18篇
  1997年   14篇
  1996年   16篇
  1995年   12篇
  1994年   8篇
  1993年   10篇
  1992年   8篇
  1991年   16篇
  1990年   19篇
  1989年   13篇
  1988年   14篇
  1987年   23篇
  1986年   23篇
  1985年   20篇
  1984年   5篇
  1983年   13篇
  1982年   7篇
  1981年   10篇
  1980年   12篇
  1979年   8篇
  1978年   4篇
  1977年   9篇
  1976年   9篇
  1971年   5篇
  1969年   4篇
  1968年   3篇
排序方式: 共有683条查询结果,搜索用时 15 毫秒
31.
32.
Insomnia is a prevalent and complex disorder to treat. This article reviews the prevalence, etiology, diagnosis and treatment of insomnia. With regard to treatment, there now exists an extensive literature demonstrating that compared with pharmacological treatments a range of non-pharmacological therapies are of proven clinical efficacy and durability. These include, for example, stimulus control therapy, bedtime restriction therapy, relaxation therapy, cognitive therapy and bright light therapy. These therapies are summarized and evaluated. It is recommended that therapists consider non-drug treatments based on cognitive-behavioral principles when managing a patient with insomnia.  相似文献   
33.
NKX3.1 is a prostate-specific homeobox gene located on chromosome 8p21. In the mouse, Nkx3.1 has growth-suppressive and differentiating effects on prostatic epithelium. Mutations of the coding region of NKX3.1 were not found in human prostate cancer, failing to support the notion that NKX3.1 was a tumor suppressor gene. To study the expression o NKX3.1 protein in human tissues and prostate cancer, we derived a rabbit antiserum against purified recombinant NKX3.1. Among normal human tissues, NKX3.1 expression was seen in testis, in rare pulmonary mucous glands, and in isolated regions of transitional epithelium of the ureter. NKX3.1 was uniformly expressed in nuclei of normal prostate epithelial cells in 61 histological sections from radical prostatectomy specimens. We analyzed 507 samples of neoplastic prostate epithelium, most of which were contained on a tissue microarray that contained samples from different stages of prostatic neoplasia. We observed complete loss of NKX3.1 expression in 5% of benign prostatic hyperplasias, 20% of high-grade prostatic intraepithelial neoplasias, 6% of T1a/b samples, 22% of T3/4 samples, 34% of hormone-refractory prostate cancers, and 78% of metastases. Our data show that NKX3.1 expression is highly, but not exclusively, specific for the prostate. Loss of NKX3.1 expression is strongly associated with hormone-refractory disease and advanced tumor stage in prostate cancer (P < 0.0001).  相似文献   
34.
35.
36.
Secondary bile acids that are formed in the colon by bacterial action have the potential property of eliciting pathological conditions. Apoptosis of mucosal epithelial cells is recognized as an adaptation that may counteract such pathologies. Cholestyramine, an anion exchange resin that sequesters bile salts in the gut, could decrease levels of secondary bile salt stress and thus conserve the potency of the protective action. Two groups of rats were studied: those fed 4% cholestyramine and those fed regular rat food. Rats were fed cholestyramine for 7, 14, 21, or 28 d. All animals were evaluated for cell death (apoptosis) using in situ TUNEL staining, and confirmed with single-stranded DNA (ssDNA). The effect of cholestyramine on the proliferating cell nuclear antigen (PCNA) in colonic crypt cells was also examined. Our data shows that animals fed cholestyramine for 28 d show evidence of a significant decrease in the levels of apoptotic cells in their large intestines, particularly goblet cells, when compared with the control animals and no change in cell proliferation. Thus, cholestyramine may serve as an alternative in attenuating apoptosis associated with inflammatory disorders that can result in significant enterocyte and goblet-cell death.  相似文献   
37.
38.
Eight patients with a tumor of the exocrine pancreas were treated or seen in consultation at the Children's Hospital Medical Center over the last 30 years. There were five girls and three boys ranging in age from 15 months to 18 years (average age: 8 years). Tumors were surgically resectable in six of eight cases--three by modified Whipple procedure and three by local resection. The average diameter of tumor was 13.6 cm (range: 3.8-20 cm). There were three adenocarcinomas of duct cell type, two acinar cell carcinomas, two acinar cell adenomas, and a papillary-cystic tumor of low-grade malignancy. One of the adenocarcinomas arose in a field of orthovoltage radiation and another occurred in a patient with tuberous sclerosis. Five of eight patients died, four with regional or distant metastases documented at autopsy. The patient with the papillary-cystic tumor experienced several local recurrences but was alive 14 years after initial surgery. Data from the literature indicate that acinar cell tumors are proportionately more common in children than in adults and have a somewhat better prognosis than tumors of duct cell type. Further reporting of cases with long-term follow-up is encouraged in order to gain clearer perspective of nonendocrine tumors of the pancreas in childhood.  相似文献   
39.
Under physician leadership, Hospice, Inc., started a home care program for terminally ill cancer patients and their families in March 1974. This paper is based on the 3-year evaluation by the medical director who argues that priority of care should be directed to physical needs, managed in a problem-oriented approach.  相似文献   
40.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号